Rozlytrek 100 & 200 Mg 100 mg, 200 mg Capsule
PDF Leaflet Revision Date: 23 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of NTRK fusion-positive solid tumours and ROS1-positive NSCLC.
Dosage (summary)
Adults: 600 mg once daily; Paediatrics: 300 mg/mu00b2 once daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
May cause fetal harm; avoid breastfeeding.
Key Drug Interactions
- Strong CYP3A inhibitors
- Moderate CYP3A inhibitors
- CYP3A inducers
Contraindications
- Hypersensitivity to entrectinib
Common side effects
- Fatigue
- Nausea
- Diarrhoea
- Cognitive disorders
- Fractures
Counselling Points
- Monitor for cognitive changes
- Avoid pregnancy
- Do not drive if affected
Serious warnings
- Congestive heart failure
- QT interval prolongation
Important Disclaimer
The Rozlytrek 100 & 200 Mg 100 mg, 200 mg Capsule professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
